Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy

Occhipinti, Vincenzo; Pastorelli, Luca

doi:10.1093/ibd/izaa084

Cited by 47 publications

(67 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to protect not only the patients, but also the health care professionals, patient visits to health institutions should be reduced to a minimum wherever possible [67]. Routine follow-up appointments of patients with IBD in remission should also be avoided if possible.…”

Section: Recommendation 13mentioning

confidence: 99%

Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers

et al. 2020

View full text Add to dashboard Cite

The COVID-19 pandemic is a global outbreak of new onset infections with the SARS-CoV-2 virus. To date, more than 3.4 million people have been infected throughout the world. In Germany, approximately 450,000 patients suffer from inflammatory bowel disease; these patients generally require continuous expert care and support. Against the background of a rapidly accumulating knowledge base on SARS-CoV-2, 68 expert authors of the current DGVS guidelines for Crohn’s disease and ulcerative colitis took part in a virtual meeting to compile up-to-date, practice-orientated recommendations aimed at improving the care of patients with IBD. These recommendations address the risk of infection, including the risk for specific patient groups, the possible course of the disease, and consequences for pharmacological and surgical therapies of the underlying disease, as well as general measures for infection prevention and adjuvant prophylactic and therapeutic options.

show abstract

Section: Recommendation 13mentioning

confidence: 99%

Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 2 , 3 Since SARS-CoV-2 may colonize the gastrointestinal tract, 4 among gastroenterologists there is concern that patients with inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), may be at increased risk of SARS-CoV-2 infection or poorer COVID-19 course, due to the chronic nature of the disease and the medications used for their treatment. 5 In fact, the therapeutic armamentarium for the management of IBD includes both steroids and immunosuppressants, which may predispose not only to opportunistic infections, but also to viral infections. 6 In the last few months, several reassuring data have been accumulating on the prevalence rate of COVID-19 and its outcomes in patients with IBD.…”

Section: Introductionmentioning

confidence: 99%

Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase

Papa

Lopetuso

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised several concerns for patients with chronic immune-mediated diseases, including inflammatory bowel disease (IBD). As the outbreak appears to be in the descending phase, at least in some part of the world, as in most European countries, guidance is urgently needed to provide optimal care for our IBD patients in order to gradually and safely reduce the gap in care that has been accumulated in the months of lockdown and to face all the backlogs. Therefore, we have provided a decalogue of practical recommendations for gastroenterologists to manage patients with IBD in the post-peak phase of the COVID-19 pandemic. They include all the aspects of IBD care, not only pharmacological ones but also endoscopy, surgery, psychological treatment, telemedicine, diagnostics and educational tasks provided by doctors and patient associations.

show abstract

“…Zum Schutz der Patienten, aber auch zum Schutz des „Gesundheitswesens“ sollte versucht werden, die Zahl der Besuche von Patienten in Einrichtungen des Gesundheitswesens möglichst gering zu halten 67 . Auf Routinevorstellungen von CED-Patienten in Remission sollte möglichst verzichtet werden.…”

Section: Kapitel 2: Diagnostikunclassified

Addendum zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch entzündlichen Darmerkrankungen in der COVID-19-Pandemie – offene Fragen und Antworten

et al. 2020

View full text Add to dashboard Cite

ZusammenfassungDie COVID-19-Pandemie ist ein weltweiter Ausbruch von neu aufgetretenen Infektionen mit dem SARS-CoV-2-Virus, von denen weltweit derzeit mehr als 10.670.000 Menschen erkrankt sind bzw. waren. In Deutschland leiden ca. 450.000 Patienten an einer chronisch entzündlichen Darmerkrankung; diese Patienten benötigen in der Regel eine kontinuierliche und kompetente Betreuung. Vor dem Hintergrund eines rasch zunehmenden Wissenszuwachses haben 68 Experten, die die derzeit gültigen Leitlinien der DGVS zum Morbus Crohn und zur Colitis ulcerosa erstellt haben, im Rahmen einer virtuellen Konferenz aktuelle und praxisnahe Empfehlungen formuliert, um die Versorgung von CED-Patienten zu verbessern. Diese adressieren das Infektionsrisiko einschließlich des Risikos für besondere Gruppen, den möglichen Verlauf der Erkrankung und die Konsequenzen für die medikamentöse und die operative Therapie der Grunderkrankung sowie allgemeine Maßnahmen zur Infektionsprävention und adjuvante Präventions- und Therapiemöglichkeiten.

show abstract

Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a “Red Zone” Area in Northern Italy

Abstract: Since February 20, 2020, in Italy, we have been confronting the dramatic challenge of the SARS-CoV-2 outbreak, which has completely overthrown our medical practice. We report our experience as an IBD center in Lombardia, the most affected region in Italy.

Cited by 47 publications

References 7 publications

Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers

Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers

Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase

Addendum zu den S3-Leitlinien Morbus Crohn und Colitis ulcerosa: Betreuung von Patienten mit chronisch entzündlichen Darmerkrankungen in der COVID-19-Pandemie – offene Fragen und Antworten

Contact Info

Product

Resources

About